Special Issue "Molecular Alterations in Thyroid Cancer – with Special Focus on Diagnosis, Prognosis and Treatment"
Deadline for manuscript submissions: 30 June 2021.
2. Department of Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden
Interests: follicular thyroid cancer; anaplastic thyroid cancer; endocrine neoplasia; endocrine pathology; next-generation sequencing; histopathology; diagnostic and prognostic markers
2. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
3. Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
Interests: papillary thyroid cancer; follicular thyroid cancer; endocrine surgery; next-generation sequencing; genetic aberrations in endocrine neoplasia; prognostic markers
2. Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden
Interests: medullary thyroid cancer; anaplastic thyroid cancer; hereditary syndromes; translational research; therapeutics; endocrine surgery
Thyroid cancer is the most common endocrine malignancy with an annual incidence of about 60,000 cases in the US and shows an increased incidence globally. The disease entity is multifaceted, and although the majority of well-differentiated forms of thyroid cancer (papillary thyroid cancer, PTC, and follicular thyroid cancer, FTC) exhibit good prognosis, other forms of thyroid cancer are often associated with dismal outcomes (poorly differentiated thyroid cancer, PDTC, and anaplastic thyroid cancer, ATC). The underlying genetic mechanisms driving thyroid cancer is only partly understood, but the advent of next-generation sequencing techniques has greatly facilitated the detection of recurrent genomic alterations of importance for disease development—of which some could be of direct clinical value.
This Special Issue will focus on molecular studies aimed at providing aid to three commonly encountered clinical dilemmas, namely (1) the diagnostic predicaments in thyroid cancer (most notably―but not limited to―the distinction of benign and malignant follicular thyroid tumors), (2) the enablement to prognosticate thyroid cancer (for example, to pinpoint the subset of thyroid cancer that recur and/or spread to distant sites) and (3) the therapeutic quandaries regarding metastatic thyroid cancer and less differentiated forms of the disease (PDTC, ATC). Further, submissions aimed at increasing our understanding of inherited forms of thyroid cancer are also warmly welcome.
Dr. Carl Christofer Juhlin
Dr. Adam Stenman
Prof. Dr. Jan Zedenius
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Papillary thyroid carcinoma
- Follicular thyroid carcinoma
- Medullary thyroid carcinoma
- Anaplastic thyroid carcinoma
- Thyroid tumors
- Molecular genetics
- Next-generation sequencing
- Clinical biomarker